Library Open Repository
Technology evaluation: MRA, Chugai
MRA.PDF | Download (52kB)
Available under University of Tasmania Standard License.
Chugai, the Japanese subsidiary of Roche, is developing a
humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
|Journal or Publication Title:||Current Opinion in Molecular Therapeutics|
|Page Range:||pp. 64-69|
|Date Deposited:||28 Mar 2008 00:57|
|Last Modified:||18 Nov 2014 03:31|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|